17α-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response

Robert D. Bruno,1 Tony D. Gover,1 Angelika M. Burger,1,2 Angela M. Brodie,1,2 and Vincent C.O. Njar1,2

1Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine; 2University of Maryland Marlene and Stewart Greenebaum Cancer Center, School of Medicine, Baltimore, Maryland

Abstract
Inhibitors of the enzyme 17α-hydroxylase/17,20 lyase are a new class of anti–prostate cancer agents currently undergoing preclinical and clinical development. We have previously reported the superior anticancer activity of our novel 17α-hydroxylase/17,20 lyase inhibitor, VN/124-1, against androgen-dependent cancer models. Here, we examined the effect of VN/124-1 on the growth of the androgen-independent cell lines PC-3 and DU-145 and found that the compound inhibits their growth in a dose-dependent manner in vitro (GI50, 7.82 μmol/L and 7.55 μmol/L, respectively). We explored the mechanism of action of VN/124-1 in PC-3 cells through microarray analysis and found that VN/124-1 up-regulated genes involved in stress response and protein metabolism, as well as down-regulated genes involved in cell cycle progression. Follow-up real-time PCR and Western blot analyses revealed that VN/124-1 induces the endoplasmic reticulum stress response resulting in down-regulation of cyclin D1 protein expression and cyclin E2 mRNA. Cell cycle analysis confirmed G1-G0 phase arrest. Measurements of intracellular calcium levels ([Ca2+]i) showed that 20 μmol/L VN/124-1 caused a release of Ca2+ from endoplasmic reticulum stores resulting in a sustained increase in [Ca2+]i. Finally, cotreatment of PC-3 cells with 5, 10, and 20 μmol/L VN/124-1 with 10 nmol/L thapsigargin revealed a synergistic relationship between the compounds in inhibiting PC-3 cell growth. Taken together, these findings show VN/124-1 is endowed with multiple anticancer properties that may contribute to its utility as a prostate cancer therapeutic. [Mol Cancer Ther 2008;7(9):2828–36]

Introduction
Prostate cancer is the most common malignancy and second leading cause of cancer-related deaths in men in the western world. The American Cancer Society estimates that, in 2008, 186,320 new cases will be diagnosed and 28,660 patients will die from the disease in the United States alone (1). Despite advances in screening and treatment of localized disease, advanced prostate cancer remains incurable.

Androgens play a vital role in the development, growth, and progression of prostate cancer (2). Therefore, androgen deprivation therapy remains the standard treatment for advanced prostate cancer. Current androgen deprivation therapy includes treatment with luteinizing hormone releasing hormone agonists and/or androgen receptor (AR) antagonists. Unfortunately, luteinizing hormone releasing hormone agonists fail to inhibit release of adrenal androgens and AR antagonists have been shown to act as partial agonists in prostate cancer cells expressing mutated and/or overexpressed AR (3, 4).

An alternative strategy for androgen deprivation therapy is the global inhibition of androgen synthesis. This can be accomplished through the inhibition of the enzyme 17α-hydroxylase/17,20-lyase (CYP17), which catalyzes two sequential and necessary reactions in the production of androgens (5). The imidazole antifungal agent ketoconazole, a nonspecific cytochrome P450 inhibitor, has been used for this indication and has shown modest efficacy in patients no longer responding to antiandrogen treatment (6, 7).

Ketoconazole treatment is, unfortunately, limited by toxicity due to its lack of specificity for CYP17. However, specific CYP17 inhibitors are emerging as a promising new class of anti–prostate cancer agents. One such molecule, abiraterone (17-(3-pyridyl)androsta-5,16-dien-3β-o1), has entered phase II clinical trials, wherein it has shown efficacy in castration refractory prostate cancer patients (8, 9). Our laboratory has carried out extensive research in this field and developed several molecules that inhibit both CYP17 and the AR directly (10). One of these compounds, a
17-benzoimidazole called VN/124-1 (Fig. 1A), has demonstrated excellent anticancer properties both in vitro and in vivo and has been shown to inhibit the growth of LAPC4 tumor xenografts more effectively than castration (11). Superior efficacy of VN/124-1 over castration in mice—which, unlike humans, do not express CYP17 in their adrenal glands and, therefore, do not secrete adrenal androgens (12)—lead us to hypothesize that the compound may have activity against androgen-independent prostate cancer cells as well. We now report that VN/124-1 and structurally related CYP17 inhibitors, including abiraterone, inhibit the growth of the androgen-independent cell lines PC-3 and DU-145 and identify the endoplasmic reticulum stress response (ERSR) as the mechanism of growth inhibition of the compound. Importantly, these effects were seen at concentrations previously shown to be achievable in both plasma and within tumors in mouse prostate cancer xenograft models (11).

As the center of protein-folding, the endoplasmic reticulum (ER) is extremely sensitive to disruptions in homeostasis, including disruptions in calcium concentrations. Such stresses induce the ERSR, also called the unfolded protein response. The ERSR is an evolutionarily conserved pathway that seeks to relieve the build-up of unfolded proteins in the ER. To achieve this, the cell first up-regulates ER resident molecular chaperones, such as glucose-regulated protein 78 (gp78/BiP; refs. 13–15), and reduces ER load through phosphorylation of the α subunit of the eukaryotic translation initiation factor 2α (eIF2α; refs. 16, 17). Phosphorylation of eIF2α results in attenuation of translation of nonessential proteins, including growth-related proteins, such as cyclin D1 (18–22). Although the ERSR is a survival pathway, prolonged stimulation of the ERSR results in growth arrest and apoptosis via the up-regulation of apoptotic-related proteins, including the CCAAT/enhancer-binding protein homologous transcription factor (CHOP; ref. 23). As a result, ERSR has been implicated in the anticancer activities of many synthetic and natural cancer therapeutics, including clotrimazole, fatty acid synthase inhibitors, Cox-2 inhibitors, 3'-diindolylmethane, and eicosapentaenoic acid (19, 24–27).

We show that VN/124-1 induces ERSR, resulting in the up-regulation of ERSR-associated genes and the phosphorylation of eIF2α. This leads to the inhibition of cyclin D1 translation, resulting in G1 arrest. Analysis of intracellular calcium signaling reveals that VN/124-1 causes the release of Ca2+ from ER, resulting in the depletion of ER calcium stores, and a sustained increase in intracellular Ca2+ concentrations ([Ca2+]i).

As VN/124-1 has recently been licensed to Tokai Pharmaceuticals, Inc. for clinical development, a complete understanding of the mechanism of actions of the molecule is important. These findings underscore the potential of VN/124-1 as an effective therapeutic for androgen-dependent and androgen-independent prostate cancer.

Materials and Methods

Compounds

VN/63-1, VN/85-1, VN/124-1, VN/125-1, and abiraterone were synthesized in our laboratory, as previously described (11, 28–30). Thapsigargin, cyclopiazonic acid, and dihydroandrosterone (DHA) were purchased from Sigma Aldrich. Compounds were dissolved in either 95% ethanol or DMSO. For all experiments, control cells were dosed with equal volume of vehicle (0.1% or less), as used in the treated groups.

Cell Culture and Viability Assays

All cell lines were obtained from American Type Culture Collection and maintained in RPMI 1640 supplemented with...
10% fetal bovine serum and 5% penicillin/streptomycin solution. Cells were grown as a monolayer in a humidified incubator (5% CO₂) at 37°C. To determine the effect of compounds on cell proliferation, cells were plated (2,500 cells per well) in 96-well cell culture dishes (Corning, Inc.). After a 24-h attachment period, medium was replaced with fresh medium containing compounds (0.01–100 μmol/L) or vehicle (95% ethanol). The cells were then allowed to grow in the presence of the drugs for 96 h. After 96 h, relative cell viability was assessed using the MTT reagent [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], as described in Patel et al. (31). Experiments were carried out thrice with six replicates per dose per experiment (n = 18). Results were plotted using the average of each dose over all three experiments and fitted with a best-fit sigmoidal dose response variable slope curve using GraphPad Prism 4.01 (GraphPad Software, Inc.). For combination of VN/124-1 and thapsigargin, cells were treated for 72 h and viability was assessed as described for single agents. Combination index was calculated, as previously described (32). Combination index values of <1 are considered synergistic.

**Microarray**

PC-3 cells were treated with (95% ethanol) or 20 μmol/L of VN/124-1. After 24-h exposure to the agent, total RNA was isolated using the Qiagen RNeasy-Mini kit following manufacturer’s protocol. Experiments were carried out in duplicate, with triplicate samples (dosed independently on three different days) from each experiment pooled for analysis on a single chip. Samples were hybridized to a GeneChip Human Genome Focus Array (Affymetrix, Inc.) and analyzed using an Affymetrix GeneChip Scanner 3000 according to manufacturer’s protocol. Gene ontologies were identified using the online Database for Annotation, Visualization, and Integrated Discovery provided by National Institute of Allergy and Infectious Diseases and NIH. Only genes that were up-regulated or down-regulated by an average of ≥2-fold and had a minimum 1.5-fold change (up or down) per array were used for this analysis. Genes that showed ≥1.5-fold change (up or down) in control samples on one or both chips were excluded. Stringent criteria of a minimum EASE/P value threshold of 0.001 and a gene count threshold of 5 were used to identify altered gene ontologies.

**Real-Time PCR**

Cells were treated and lysed, and RNA were collected and quantified using the same method outlined above. Cells were dosed independently on three separate days (n = 3). One microgram of total RNA was converted to cDNA using ReactionReady First Strand cDNA Synthesis kit (SuperArray Bioscience Corp.) following the manufacturer’s protocol. Template cDNA (50 ng) was then used in subsequent quantitative real-time PCR (qRT-PCR) reactions. Template was combined with target gene specific or β-actin control RT² PCR Primer Sets, RT² Real-Time@ SYBR Green/Rox Master Mix (SuperArray Bioscience Corp.), and double-distilled water for a final reaction volume of 25 μL and run on a 7900HT Fast Real-Time PCR system (Applied Biosystems) following the manufacturer’s protocol. Fold changes were calculated using the ΔΔCt method, as recommended by the manufacturer’s protocol.

**Cell Cycle Analysis**

Cells were synchronized in the G1-G0 phase by maintaining them in 0.2% fetal bovine serum-containing medium for 96 h. After starvation, medium was replaced with normal growth medium (10% fetal bovine serum) containing vehicle (95% ethanol) or 20 μmol/L VN/124-1 for 12, 18, and 24 h. At each time point, cells were fixed in 70% ethanol at −20°C for at least 24 h. Fixed cells were then incubated with 1 mL propidium iodide staining buffer (1 mg/mL propidium iodide, 0.1% Triton-X, and10 μg/mL RNase A dissolved in PBS) for 1 h at room temperature, and DNA content was measured by flow cytometry analysis using a FACSort flow cytometer (Becton Dickinson); 15,000 events were analyzed for each sample. ModFit LT version 3.1 (Verity Software House Ind.) was used to analyze cell cycle distribution.

**Western Blot**

Cells were treated with VN/124-1, DHA, thapsigargin, or vehicle for 6 and 24 h. Protein was isolated, subjected to SDS-PAGE, transferred, and imaged, as previously described (33). All primary antibodies were purchased from Cell Signaling. Quantitation of relative protein expression was determined via densitometry using the software ImageQuant 5.0 (Molecular Dynamics), with each protein normalized to its respective loading control. Results represent the average of at least three independent experiments, with representative blots shown.

**Ca²⁺ Measurements**

PC-3 Cells were loaded with either fura-2 or fluo-3 indicator by incubation with 2 μmol/L fura-2/AM or 2 μmol/L fluo-3/AM in RPMI 1640 containing 10% fetal bovine serum for >60 min at room temperature. During experiments, the coverslips were mounted in a flow chamber and superfused with oxygenated Locke solution containing (in mmol/L) 10 glucose, 136 NaCl, 5.6 KCl, 1.2 NaH₂PO₄, 14.3 NaHCO₃, 1.2 MgCl₂, and 2.2 CaCl₂ (pH 7.4) at room temperature (22–24°C).

For measurement of [Ca²⁺] in individual cells, PC-3 cells were treated with 1, 5, 10, and 20 μmol/L VN/124-1, 20 μmol/L DHA, or vehicle. Cells loaded with fura-2 were placed in a perfusion chamber mounted on an inverted microscope (TE200; Nikon) equipped with a UV-transmitting objective (SuperFluor, 40×, N.A. 1.4, Nikon). Fura-2 was alternately excited by 340 and 380 nm light from monochrometers (Deltascan Illumination System, Photonics Technology International), and fura-2 emission was passed through a 515-nm longpass filter before detection by a cooled CCD camera (Retiga 2000R, Q-Imaging). For measurement of [Ca²⁺] transients in individual cells, coverslips with fluo-3-loaded cells were excited by the output of a 100-W mercury arc lamp that passed through a 480-nm bandpass filter (30 nm bandwidth). Fluorescence emission was passed through a 515-nm longpass filter before capture by a cooled CCD camera (Retiga 2000R, Q-Imaging).
Q-Imaging). Image acquisition was done with QCapture Pro (Q-Imaging), and analysis was done with ImageJ (U.S. NIH).

Fluo-3 Ca\(^{2+}\) indicator measurements are reported as the fractional change in fluorescence intensity relative to baseline ($\Delta F/\Delta F_0$), which was determined as follows. Within a temporal sequence of fluorescence images, a region of interest was drawn around each cell to be analyzed. The fluorescence signal from each cell was calculated as the pixel-averaged intensity within each region of interest. In these experiments, we typically observed a slight downward drift in baseline, which was principally

**Table 1. Growth inhibitory effects of steroidal lyase inhibitors against PC-3, DU-145, and LNCaP cells**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cell line</th>
<th>GI(_{50}) (µmol/L)</th>
<th>95% CI (µmol/L)</th>
<th>GI(_{90}) (µmol/L)</th>
<th>95% CI (µmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VN/63-1</td>
<td>PC-3</td>
<td>2.91</td>
<td>1.14–11.57</td>
<td>&gt;100</td>
<td>—</td>
</tr>
<tr>
<td>VN/85-1</td>
<td></td>
<td>1.86</td>
<td>1.31–2.86</td>
<td>30.41</td>
<td>13.18–67.61</td>
</tr>
<tr>
<td>VN/125-1</td>
<td></td>
<td>1.41</td>
<td>1.22–1.60</td>
<td>8.07</td>
<td>6.61–9.80</td>
</tr>
<tr>
<td>Abiraterone</td>
<td></td>
<td>9.32</td>
<td>8.69–9.94</td>
<td>&gt;100</td>
<td>—</td>
</tr>
<tr>
<td>VN/63-1</td>
<td>DU-145</td>
<td>11.04</td>
<td>4.75–22.74</td>
<td>&gt;100</td>
<td>—</td>
</tr>
<tr>
<td>VN/85-1</td>
<td></td>
<td>5.31</td>
<td>3.71–7.22</td>
<td>31.62</td>
<td>23.12–40.58</td>
</tr>
<tr>
<td>VN/124-1</td>
<td></td>
<td>7.55</td>
<td>6.90–8.11</td>
<td>15.95</td>
<td>13.86–18.24</td>
</tr>
<tr>
<td>Abiraterone</td>
<td></td>
<td>14.68</td>
<td>13.42–15.95</td>
<td>&gt;100</td>
<td>—</td>
</tr>
<tr>
<td>VN/63-1</td>
<td>LNCaP</td>
<td>1.05</td>
<td>0.69–1.55</td>
<td>&gt;100</td>
<td>—</td>
</tr>
<tr>
<td>VN/85-1</td>
<td></td>
<td>2.47</td>
<td>1.55–3.96</td>
<td>36.49</td>
<td>23.03–58.74</td>
</tr>
<tr>
<td>VN/124-1</td>
<td></td>
<td>3.15</td>
<td>2.41–4.17</td>
<td>31.99</td>
<td>23.82–45.01</td>
</tr>
<tr>
<td>VN/125-1</td>
<td></td>
<td>1.18</td>
<td>0.95–1.48</td>
<td>13.46</td>
<td>9.80–18.01</td>
</tr>
<tr>
<td>Abiraterone</td>
<td></td>
<td>1.41</td>
<td>0.95–1.96</td>
<td>25.12</td>
<td>14.19–100</td>
</tr>
</tbody>
</table>

**NOTE:** Cells were treated with various concentrations of each compound for 96 h, and cell viability was assessed by MTT assay, as described in Materials and Methods. GI\(_{50}\) and GI\(_{90}\) values were calculated from sigmoidal-dose response curves (variable slope) generated from three independent experiments. Abbreviation: 95% CI, 95% confidence interval.

**Table 2. VN/124-1 up-regulated and down-regulated ontologies**

<table>
<thead>
<tr>
<th>Count</th>
<th>%</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up-regulated ontology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Response to stress</td>
<td>16</td>
<td>24.24</td>
</tr>
<tr>
<td>Amino acid metabolism</td>
<td>8</td>
<td>12.12</td>
</tr>
<tr>
<td>Amine metabolism</td>
<td>9</td>
<td>13.64</td>
</tr>
<tr>
<td>Nitrogen compound metabolism</td>
<td>9</td>
<td>13.64</td>
</tr>
<tr>
<td>Amino acid and derivative metabolism</td>
<td>8</td>
<td>12.12</td>
</tr>
<tr>
<td>Negative regulation of biological process</td>
<td>12</td>
<td>18.18</td>
</tr>
<tr>
<td>Negative regulation of cellular process</td>
<td>11</td>
<td>16.67</td>
</tr>
<tr>
<td>Development</td>
<td>18</td>
<td>27.27</td>
</tr>
<tr>
<td>Carboxylic acid metabolism</td>
<td>9</td>
<td>13.64</td>
</tr>
<tr>
<td>Organic acid metabolism</td>
<td>9</td>
<td>13.64</td>
</tr>
<tr>
<td>Response to external stimulus</td>
<td>9</td>
<td>13.64</td>
</tr>
<tr>
<td>Down-regulated ontology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA replication</td>
<td>17</td>
<td>34.69</td>
</tr>
<tr>
<td>DNA metabolism</td>
<td>19</td>
<td>38.78</td>
</tr>
<tr>
<td>DNA-dependent DNA replication</td>
<td>10</td>
<td>20.41</td>
</tr>
<tr>
<td>Cell cycle</td>
<td>16</td>
<td>32.65</td>
</tr>
<tr>
<td>Biopolymer metabolism</td>
<td>27</td>
<td>55.1</td>
</tr>
<tr>
<td>Regulation of progression through cell cycle</td>
<td>10</td>
<td>20.41</td>
</tr>
<tr>
<td>Regulation of cell cycle</td>
<td>10</td>
<td>20.41</td>
</tr>
<tr>
<td>Nucleobase, nucleoside, nucleotide and nucleic acid metabolism</td>
<td>24</td>
<td>48.98</td>
</tr>
<tr>
<td>Macromolecule metabolism</td>
<td>28</td>
<td>57.14</td>
</tr>
<tr>
<td>Second messenger–mediated signaling</td>
<td>6</td>
<td>12.24</td>
</tr>
</tbody>
</table>

**NOTE:** Up-regulated and down-regulated ontologies were identified using Database for Annotation, Visualization, and Integrated Discovery, as described in Materials and Methods for genes up-regulated in PC3 cells by 24-h exposure to 20 µmol/L VN/124-1, as determined by affymetrix human focus microarray. P values are based on an enrichment (EASE) score.
attributable to photo-bleaching of the indicator. In such cases, the drift was always well fit by a low-amplitude single-exponential decay. The fitted baseline value \( F_0 \) at every time point was then used to calculate \( \Delta F/F_0 \). \( \Delta F/F_0 \) values are reported as mean ± SE. For fura-2 measurements, \([Ca^{2+}]\) was derived using the ratio method of Grynkiewicz et al. (34).

**Statistical Analysis**

qRT-PCR results for each gene were analyzed via a Student’s t test comparing \( \Delta C_T \) values (\( C_T \) value of test gene minus \( \beta\)-actin control). Western blots and combination growth studies were analyzed with Kruskal-Wallis and Dunn’s multiple comparison post-hoc tests. Flow cytometry data was analyzed with Student’s t test. \([Ca^{2+}]\) data was analyzed with one-way ANOVA with Dunnett’s post-hoc test.

**Results**

**VN/124-1 and Related C-17 Steroidal Azoly compounds Inhibit the Growth of Androgen-Independent Prostate Cancer Cell Lines**

To determine if VN/124-1 exerts a direct cytotoxic/cytostatic effect, we treated the androgen-independent prostate cancer cell lines PC-3 and DU-145 with increasing concentrations of VN/124-1 and found that the compound inhibited both cell lines in the low micromolar range (Fig. 1B–D; Table 1). The potency of VN/124-1 against PC-3 and DU-145 cell lines was comparable with that seen with androgen-dependent LNCaP cells (low micromolar range). Structurally related steroidal C-17–substituted lyase inhibitors VN/63-1, VN/85-1, VN/125-1, and abiraterone also inhibited the growth of PC-3 and DU-145 cells (Table 1). The structurally related androgen DHA, however, was almost a 10-fold less potent than VN/124-1 in inhibiting PC-3 cells and lacked any growth inhibitory activity against DU-145 cells up to 100 \( \mu \)mol/L. Inhibition of LNCaP cell viability in vitro was previously attributed to the ability of VN/124-1 to act as an AR antagonist. However, as PC-3 and DU-145 cells are well-established androgen-independent cell lines that do not express a functional AR (35), it is clear from these results that these compounds also have activities distinct from the androgen axis.

**Microarray Analysis Reveals VN/124-1 Induces the Down-regulation of Cell Cycle – Related Genes and Up-regulation of Genes Involved in Cellular Response to Stress in PC-3 Cells**

To shed light on the mechanism of action of VN/124-1, PC-3 cells were treated with 20 \( \mu \)mol/L (~G1G0) of the compound for 24 hours and global gene expression changes were measured using a GeneChip Human Genome Focus Array. We used the online Database for Annotation, Visualization, and Integrated Discovery to identify clusters of related genes affected by VN/124-1. As shown in Table 2 (top), the most enriched up-regulated ontologies are those relating to stress and metabolism, in particular amino acid metabolism. Nearly all of the down-regulated ontologies (Table 2, bottom) are associated with the cell cycle, especially the S-phase (DNA replication). Interestingly, induction of genes involved in amino acid metabolism has been shown to occur after induction...
of ER stress (36), and the ERSR is known to block the transition to S-phase of the cell cycle. These preliminary findings lead us to hypothesize that VN/124-1 may inhibit growth via induction of the ERSR.

**VN/124-1 Induces Genes Involved in ER-Stress Response**

We next sought to validate the gene expression changes of specific genes found to be altered by VN/124-1 in the microarray experiment by using qRT-PCR (Fig. 2A). The most highly up-regulated gene found in the microarray was S100P calcium binding protein (S100P). S100P is a member of the S100 family of proteins, all of which take part in Ca²⁺ signaling. Surprisingly, S100P has been shown to be involved in the growth and survival of cancer cells and is a negative prognostic marker of disease progression (37, 38). The functional significance of this remains unknown, but interestingly, S100P has been reported to be up-regulated by other chemotherapeutics and natural anticancer agents, including DNA cross-linking agents and all-trans retinoic acid (39, 40). Other genes verified by qRT-PCR that were up-regulated in the microarray experiment include asparagines synthetase and activating transcription factor 4. Both of these genes have been reported to be up-regulated by the ERSR (25). CHOP was not included in the microarray but is a marker for the ERSR (23), and qRT-PCR revealed it to be strongly up-regulated by VN/124-1. We also looked at the expression of the G₁ cyclins D1 and E2. Interestingly, cyclin D1 mRNA levels were not affected by VN/124-1, but the downstream cyclin E2 was significantly reduced. These results were very similar to those seen in the microarray.

**VN/124-1 Induces ERSR-Related Proteins, Phosphorylation of eIF2α, and Down-regulation of Cyclin D1**

To confirm ERSR as a mechanism of VN/124-1 action, we next analyzed the effect of the drug at the protein level. PC-3 cells were treated with VN/124-1 for 6 and 24 hours. As shown in Fig. 2B, 20 μmol/L VN/124-1 induced the phosphorylation of eIF2α at 6 and 24 hours. The drug also significantly induced the expression of the molecular chaperone gp78/BiP, a well-established marker of ER stress (13–15), in a dose-dependent manner. As mentioned previously, phosphorylation of eIF2α attenuates translation of many transcripts, including cyclin D1. This was confirmed as VN/124-1 induced the down-regulation of cyclin D1 protein significantly after 24 hours. As discussed above, VN/124-1 had no effect on cyclin D1 mRNA levels, suggesting this down-regulation is indeed occurring at the translational level. Of note, treatment with 20 μmol/L DHA had no significant effect on any of the protein markers measured. Taken together, these findings strongly support the hypothesis that VN/124-1 induces the ERSR.

**VN/124-1 Induces G₁-G₀ Growth Arrest**

We next analyzed the effect of VN/124-1 on cell cycle distribution in PC-3 cells. We found that treatment with 20 μmol/L VN/124-1 prevented the exit from G₁ phase of the cell cycle in synchronized cells (Fig. 2C). This resulted in a significant increase in the amount of cells in G₁-G₀ at 18 and 24 hours. These findings are in line with the loss of cyclin D1 protein expression and subsequently cyclin E2 transcription, as both are needed for transition to the S-phase of the cell cycle (41). This is also in accord with the microarray data showing VN/124-1 down-regulates genes involved in DNA replication.

**VN/124-1 Induces Release of Ca²⁺ from ER Stores**

We next sought to answer the question of how VN/124-1 induces ER stress. Some structurally related compounds, including 3β,1-diindolylmethane and imidazole containing antifungals, such as clotrimazole and econazole, have been shown to elicit the ERSR by disrupting ER calcium homeostasis (19, 42, 43). To determine if VN/124-1 induces
the ERSR in a similar manner, we treated PC-3 cells with 20 μmol/L VN/124-1 and measured relative changes in intracellular calcium concentrations [Ca²⁺], using the calcium-sensitive fluorescent dye Fluo-3AM. As seen in Fig. 3A, VN/124-1 induced an immediate transient increase in [Ca²⁺], (mean ΔF/F₀ = 0.613). This transient was not reduced when extracellular calcium was removed from the bath (mean ΔF/F₀ = 0.967; Fig. 3B) but was completely abolished when ER calcium stores were depleted by pretreatment with the sarco/ER Ca²⁺-ATPase inhibitor cyclopiazonic acid (Fig. 3C). Finally, we measured the sustained effect of VN/124-1 on absolute [Ca²⁺], using Fura-2AM. PC-3 cells were treated for 2 hours with vehicle, DHA, or increasing concentrations of VN/124-1 (Fig. 3D). Control cells had an average [Ca²⁺] of 36.49 nmol/L, whereas cells treated with 5, 10, and 20 μmol/L VN/124-1 had a significant increase in [Ca²⁺], (79.13, 96.63, and 79.89 nmol/L, respectively). Treatment with DHA or 1 μmol/L VN/124-1 did not have a significant effect on [Ca²⁺]. These results clearly show that VN/124-1 is inducing Ca²⁺ release from ER stores, resulting in a sustained increase in [Ca²⁺].

**Discussion**

Inhibitors of CYP17 are an exciting new class of potential prostate cancer therapeutics. As these drugs enter clinical trials, complete understanding of their mechanisms of action is important in evaluating their efficacy and safety. In the present study, we show that the CYP17 inhibitor/antiandrogen VN/124-1, as well as other structurally related CYP17 inhibitors, exerts direct growth inhibitory actions against the androgen-independent cell lines PC-3 and DU-145. As these actions were seen in the low micromolar range, it is important to note that peak plasma concentrations of abiraterone (given clinically as the prodrug abiraterone acetate) are below 1 μmol/L (44), suggesting these findings may not be relevant for that compound. However, preclinical kinetics data of VN/124-1 has shown that concentrations above 20 μmol/L are achievable in mouse in vivo models (11), indicating that these findings are physiologically relevant.

Using various molecular, pharmacologic, and biochemical techniques, we were able to identify the likely mechanism of VN/124-1 action against androgen-independent prostate cancer cells (Fig. 4B, right). VN/124-1 induces the rapid release of Ca²⁺ from ER, resulting in a sustained increase in [Ca²⁺]. This disruption in Ca²⁺ homeostasis induces ERSR, resulting in the up-regulation of ERSR-related genes and the phosphorylation of eIF2α. Phosphorylation of eIF2α attenuates the translation of several progrowth genes, including cyclin D1. The loss of cyclin D1 prevents exit from the G1-phase of the cell cycle, thereby inhibiting the growth of cells.

It remains unclear how VN/124-1 induces release of Ca²⁺ from ER. Interestingly, the compound was shown to act synergistically with thapsigargin, suggesting VN/124-1 works through a separate mechanism. Still, disruptions in Ca²⁺ and induction of ERSR are likely not to be selective for cancer cells in vitro. However, there is a growing belief that agents that induce the ERSR may exhibit some specificity for tumors in vivo, as it is well documented that tumors are under constant low levels of ER stress (45). This is in large part due to the hypoxic conditions of the tumor microenvironment. Recent studies with the ERSR-inducing compound, 3β3-dindolylmethane, showed that cancer cells were sensitized to the drug when cotreated not only with thapsigargin but also in medium deficient in leucine and...
supplemented with 2-deoxyglucose and the Hif1α inducer CoCl2 to simulate the hypoxic and nutrient-deficient environment of the tumor (25). Therefore, it is possible that a therapeutic window exists where VN/124-1 could be used to treat androgen-independent prostate cancer without significant toxicity.

It remains unclear as to how VN/124-1 induces Ca2+ release from ER. It may be through a direct or indirect mechanism, such as the production of reactive oxygen species—as has been shown with the imidazole containing antifungal econazole (43). Future studies will seek to answer this question, as well as the efficacy of VN/124-1 against androgen-independent in vivo models of prostate cancer.

VN/124-1 seems to be endowed with multiple pharmacologic properties that add to its utility as a prostate cancer therapeutic. Figure 4B outlines all of the androgen-dependent and androgen-independent mechanisms of VN/124-1. The major mechanism of VN/124-1 remains inhibition of CYP17, which is achieved in the low nanomolar range. However, previous studies have shown high doses (0.15 mmol/kg bd) were capable of inhibiting tumors significantly better than castration in vivo (11), suggesting that the ability of VN/124-1 to induce ERSR may play a role at such doses. The findings outlined in this study represent a major step forward in the understanding of the mechanism of action of VN/124-1 and underscore its potential to be used to treat all phases of prostate cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank UMB Bipolymer Core Facility for their assistance in the microarray and qRT-PCR experiments, UMB Flow Cytometry Core Facility for their assistance with cell cycle experiments, and Dr. Daniel Weinrich for the use of his laboratory for Ca2+ measurement studies.

References


17α-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response
